思宇往期活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 由思宇MedTech主办的 第二届全球医疗科技大会 ， 将于2025年7月17日在北京中关村展示中心举行。作 为专注于医疗器械的高规格行业大会，企业参展不仅是一次线下交流，更是一次精准的品牌曝光机会。 大会 聚焦"前沿技术 · 从研发走向临床应用" 。目前， 招商已经开始， 展位有限，欢迎有意企业抓紧对接。 权益包括但不限于： 商务合作，联系方式如下。 # 大会概况 一、会议地点 ： 中关村展示中心会议中心（北京市海淀区新建宫门路2号） 六、大会议程（拟） 工作微信号： suribot22 手机号： 13552754250 也可以直接联系主编赵清、Alice、Jacky、Ziana 等任何思宇团队的工作人员。 以下为思宇此前举办的大会展位示意图，供参考： 主题演讲 大会现场品牌展位 企业宣传资料发放 活动现场环节嵌入品牌标识 本次大会将邀请来自影像设备、AI平台、高值耗材、能量系统、材料技术等方向的上市公司、创业企业等，分 享 产品创新、技术落地、医工协同等方面的实践经验。 本届大会将重点探讨以下话题 ...

康基医疗 20250703 摘要 全球微创外科耗材市场规模庞大，2024 年约为 320 亿美元，但年复合 增速仅为 5%，主要受欧美老龄化及欠发达地区开胸手术影响。中国市 场增速显著，预计未来五年复合增速达 12%，2024 年市场规模预计为 260 亿元，2028 年将达 407 亿元。 微创外科手术量在中国持续增长，预计从 2023 年的 1,400 万台增至 2028 年的 2,400 万台，耗材单价略有提升。集采政策导致穿刺器等产 品价格大幅下降，外资企业因成本压力退出，为康基等国产企业提供了 巨大的替代空间。 康基医疗的市场份额显著提升，从 2019 年的 2%-3%增长至 2023 年 的 14%左右，受益于国产替代加速。国际巨头如美敦力因成本问题退出 部分产线，其原副总裁也转投康基，进一步增强了康基的竞争力。 康基医疗在一次性穿刺器、高分子结扎夹、电凝钳等领域占据领先地位， 并积极拓展超声刀、吻合器和缝线等产品线。同时，康基也在腹腔机器 人领域进行布局，其子公司正在开发相关产品。 Q&A 康基作为中国微创耗材的龙头企业，在手术机器人领域的发展前景如何？ 康基发布了其第一款腹腔镜手术机器人，预计 ...

新氧 20250701 摘要 截至上一季度末，我们共开设了 23 家店铺，目前已增至 31 家。2025 年计划 将门店数量增加到 50 家，主要集中在北京、上海、深圳和杭州等一线城市， 以进一步加密布局。 请详细介绍一下标准门店模型，包括收入、成本结构以及盈利情况。 成熟期门店月均收入在 450 万至 500 万人民币之间，而成长期门店月均收入 约为 300 万人民币。成本结构分为变动成本和固定成本，其中变动成本包括营 销费用，占比约 15%，耗材流通成本占比 49%至 50%。固定成本包括人员费 用（12%）、房租水电（10%至 15%）以及设备折旧费用（10%）。 成熟期与成长期门店分别有多少？各阶段门店的发展情况如何？ 新氧通过信息服务费和佣金切入医美市场，向上游收购武汉奇致激光 （7.9 亿人民币），拓展光电设备业务，并代理韩国东邦玻尿酸产品， 上季度出货 2.8 万只，同比增长 14%。 新氧青春诊所是下游核心业务，已开设 31 家门店，主打青春原创（如 超声线雕 999 元）、玩具大师团（客单价 3-4 万元）和经典系列产品， 计划 2025 年扩张至 50 家，集中在一线城市。 成熟期门店月均 ...

Core Viewpoint - Mindray Medical aims to become one of the top ten or even top five medical device companies globally, leveraging its strong competitive position in the Chinese market, particularly in the monitoring equipment sector [4]. Group 1: Investor Relations Activities - Mindray Medical conducted a series of investor relations activities from May 19 to June 27, 2025, attracting 382 institutions and 713 investors [3]. Group 2: Competitive Advantages - The company's success is attributed to its meticulous attention to detail and solid execution across R&D, management, and sales, alongside a strong focus on employee training and welfare [5]. Group 3: Addressing Performance Challenges - Mindray identified reasons for slowing growth, including post-pandemic demand decline and trade friction, and is focusing on high-end market needs and overseas expansion to regain rapid growth [6]. Group 4: Domestic Policy Adaptation - The company views centralized procurement policies as a necessary step towards market maturity in China, which ultimately presents opportunities for leading domestic firms [7]. Group 5: International Strategy - Mindray aims for international revenue to account for 70% of its total, with over 60 overseas subsidiaries and a focus on local production and compliance with international regulations [8]. Group 6: Business Transformation - The company is preparing for a transformation in its business model by acquiring Huatai to enhance its core technology and expand into high-value consumables [9]. Group 7: Product Development and Market Position - Mindray is narrowing the gap with Roche in the chemiluminescence sector through strategic acquisitions and local production, with confidence in competing with imported brands [10]. Group 8: Data Integration and Device Advantage - The "Ruizhi Lian" data platform integrates with most mainstream devices, providing comprehensive and accurate patient data, which is a significant competitive edge [12]. Group 9: R&D Resource Allocation - The company balances R&D resources to support both core and emerging businesses, ensuring stability in main operations while fostering new growth areas [13]. Group 10: Personalized Product Development - Mindray conducts market research in target countries during product development, ensuring that products meet local clinical needs before full market launch [14]. Group 11: IVD Product Line Improvements - Mindray's MT8000 product line addresses inefficiencies found in imported brands, with ongoing efforts to enhance functionality and adapt to European market needs [15]. Group 12: MPI System Adaptation - The company is refining its MPI system to better suit the needs of its IT and consumable businesses, ensuring rapid iteration and effective project execution [16]. Group 13: Growth Challenges and Strategies - Mindray recognizes its limitations in marketing and local delivery for high-value consumables and is considering both internal development and acquisitions to address these gaps [18]. Group 14: "Sanrui" Ecosystem Strategy - The "Sanrui" ecosystem model is designed to integrate clinical data and enhance automation and intelligence in medical devices, with plans for local deployment and information security [19]. Group 15: Innovation in Product Development - Mindray emphasizes technical innovation, focusing on user needs and product performance, as demonstrated by the successful launch of its ultrasound knife [20]. Group 16: Company Overview - Founded in 1991, Mindray Medical is China's largest medical device manufacturer, with a global presence and a strong R&D team [21]. Group 17: Financial Performance - In 2024, Mindray reported a revenue of 36.73 billion, a 5.1% increase year-on-year, with a net profit of 11.67 billion, reflecting a 0.7% growth [22].

微创外科行业专题 20260629 摘要 创新药板块是医药行业亮点，基本面强劲，标的扩散且行情持续。近期 回调属正常调整，受短期涨幅过快和市场谣言扰动影响，但长期发展趋 势不变，调整后或迎来第二次上涨。 医疗设备板块基本面持续环比改善，预计三季度同比显著改善。重点关 注高端医学影像设备、人工智能医疗器械、医用机器人等领域，推荐迈 瑞、联影、奥华、开利、祥生等公司。 原料药板块整体行情看好，存量品种价格触底，产能利用率提升。三大 成长点包括专利到期新品种、制剂一体化业务和成本领先型 CDMO。天 宇股份等公司业绩逐步验证超预期表现。 中药板块预计下半年环比向好，受益于业绩基数下降和中药材采购成本 下降。推荐华润三九、马应龙、康缘和天士力等企业，这些企业估值普 遍在 15 倍左右，与稳健增长预期相匹配。 线下零售药店关店速度或将提升，但头部集中度将提升。线上渠道对线 下替代率长期看仍会持续提升，由医保改革及巨头加码驱动。看好京东 健康，建议线下药房进行门店调整升级。 Q&A 今年医药行业的整体表现如何？哪些板块表现较好？ 今年医药行业整体表现不佳，在 31 个一级行业中排名第 23。相对表现较好的 主要集中在创新 ...

Core Viewpoint - The company has decided to terminate part of its fundraising projects and delay others, based on a careful assessment of the current market conditions and project progress, ensuring that these decisions align with the long-term interests of the company and its shareholders [1][10]. Fundraising Overview - The company raised a net amount of RMB 1,002,572,682.71 through its initial public offering, verified by an accounting firm [1]. - The company has established a management system for the use of raised funds, ensuring that funds are stored in dedicated accounts and used strictly for their intended purposes [2]. Termination of Fundraising Projects - The project "Zihang Medical Device Component Intelligent Manufacturing and Expansion Project" will be terminated, with the total investment amount reduced from RMB 282.84 million to RMB 143.47 million, and the fundraising investment amount decreased from RMB 282.84 million to RMB 135.77 million [3]. - The termination is influenced by changes in market demand and increased competition, leading to a reassessment of the project's viability [6][7]. Reasons for Project Termination - The implementation of centralized procurement policies has created volatility in market demand, affecting the sales cycle and capacity planning for the project [6]. - The existing production capacity is deemed sufficient to meet current demand, and further investment could lead to idle capacity risks [7]. Impact of Project Termination - The termination is expected to enhance the efficiency of fundraising usage and will not adversely affect the company's normal operations or shareholder interests [8]. - The remaining funds from the terminated project will be retained in dedicated accounts for future investment opportunities [8]. Delay of Fundraising Projects - The "Weike Medical Minimally Invasive Surgical New Product Project" will be delayed, with the expected completion date pushed from June 30, 2025, to December 31, 2027 [9]. - The delay is attributed to changes in market conditions and the need for further product development to meet diverse customer needs [9]. Reasons for Project Delay - The company is adapting to market changes and enhancing product features through increased R&D investment, which has necessitated a phased approach to project implementation [9]. - The execution of procurement policies has affected the expected market release timeline for the company's products [9]. Impact of Project Delay - The delay is a strategic decision that does not involve changes to the project’s implementation structure or total investment, ensuring that it aligns with the company's long-term development goals [9][10].

证券之星消息，2025年6月20日皖仪科技（688600）发布公告称公司于2025年6月10日接受机构调研，鑫元 基金、上海歌汝私募基金、上海磐厚投资、上海明汯投资、上海健顺投资、杭州拾年投资、上海犁得尔私 募基金、泰康基金、民生加银基金、陆家嘴国际信托、兆顺基金、嘉实基金、浩成资产、深圳前海华杉投 资、国金证券、东莞证券、财通证券、西部证券、上海弘尚资产、交银施罗德基金、和谐健康保险、金元 证券资管、天弘基金、西部利得基金、融通基金、平安基金、上海南土资产、湖南省财信信托、深圳市远 望角投资、国丰兴华私募基金、上海懿坤资产、汇丰晋信基金、青骊投资、泓德基金、北京沣沛投资、深 圳旦恩先锋投资、厦门双泓元投资、天和思创投资、华富基金、苏州君榕资产、中银基金、国泰海通证 券、英大证券、上海证券、招商基金、华宝证券、广发基金、长盛基金、华西基金、建信基金、银华基 金、涌贝资产、华夏久盈、华夏基金、广东正圆私募基金、上海途灵资产、北京兴源投资、永赢基金、厦 门中略投资、上海运舟私募基金、上海卫宁私募基金、上海瓦洛兰投资、银河基金、广州瑞民投资、上海 混沌投资、深圳望正资产、华商基金、循远资产、中景润控股集团、长江证券 ...

Core Viewpoint - The article highlights the rising popularity of the American version of ultrasound knife technology in the anti-aging sector, emphasizing its effectiveness and precision in achieving facial lifting and tightening results [1][3]. Group 1: Technology and Effectiveness - The American ultrasound knife is recognized for its strong lifting effect, improving skin elasticity and reducing wrinkles, leading to clearer facial contours [3]. - This technology has received FDA certification, ensuring its safety and effectiveness [3]. - It utilizes high-intensity focused ultrasound to target the SMAS layer, tightening loose muscle tissue and providing long-lasting lifting effects [3]. Group 2: Precision and Customization - The ultrasound knife's precision is enhanced by real-time imaging technology, allowing doctors to observe skin structure and adjust treatment depth and energy according to individual skin conditions [3]. - The Ulthera® specialized probe can be customized for different depths (1.5mm, 3.0mm, 4.5mm) to treat various skin layers, achieving natural and effective lifting and tightening results [3]. Group 3: VelyB Hospital's Role - VelyB Hospital is recognized for its strong reputation in the medical aesthetics field and has introduced advanced technologies like the American ultrasound knife as part of its anti-aging strategy [6]. - The hospital boasts a skilled medical team trained in the operation of the ultrasound knife, capable of creating personalized treatment plans based on individual facial characteristics and needs [6]. - Various treatment options are available at VelyB Hospital, including different shot counts (100, 300, 600), catering to diverse client needs from mild skin laxity to significant facial sagging [6].

皖仪科技 20250617 摘要 皖仪科技正经历战略转型，从传统工业环境产品向半导体和工业领域拓 展，并积极发展医疗仪器业务，如超声刀和血液透析仪，其中超声刀已 进入集采，展现多元化发展潜力。 在可控核聚变领域，皖仪科技提供高精度真空检漏解决方案，核心产品 包括氦质谱检漏仪等，并已成为合肥聚变产业联盟理事会成员，占据该 领域 2%-3%的造价成本比例。 皖仪科技的氦质谱检漏技术达到国际领先水平，最小可检测 5×10^-13 帕立方米每秒的漏孔，并开发出国内尚无其他企业能够实现的模块式检 测系统，具备显著竞争优势。 半导体领域是皖仪科技重点拓展方向，其氦质谱检漏仪广泛应用于单晶 炉管道、CVD、PVD 等制造环节，并积极研发参研气体分析仪和真空计， 对标国际领先企业。 受益于地缘政治影响，分析仪器市场国产替代需求增加，皖仪科技加大 研发投入，特别是在液相色谱领域取得进展，并调整销售模式，从以代 理商为主转变为以直销为主，提升毛利率。 Q&A 请介绍一下皖仪科技的主要业务和历史背景。 皖仪科技坚持中高端市场定位，对标国际先进产品，通过技术创新和性 能提升，在中高端气体分析仪市场占据优势，并积极拓展核电方向定制 化 ...

从全球范围看，医疗器械产业已逐渐成为发展速度快、贸易活跃、产品附加值高的新兴产业之一，医疗器械市场规模逐年增长，也为中国医疗器械企业提供 了广阔的出海空间。在此基础上，近年来，中国创新医疗器械成果大量涌现，正处于出海造福全球患者的关键阶段。越来越多具有全球化视野、技术先进、 合规运营、产品质量上乘的中国企业正在国际化进程中脱颖而出，逐渐展现国际影响力，包括联影、迈瑞在内的医疗器械设备巨头都开始加速出海。 越来越多具有全球化视野、技术先进、合规运营、产品质量上乘的中国企业正在国际化进程中脱颖而出，逐渐展现国际影响力，包括联影、迈瑞在内的医疗 器械设备巨头都开始加速出海。 今日A股开盘后，医疗设备巨头公司股价承压。联影医疗（688271.SH）股价一度下跌近6%，迈瑞医疗（300760.SZ）股价下跌近2%，鱼跃医疗 （002223.SZ）股价下跌近3%。 前一日消息称，欧盟拟根据《国际采购工具》对中资企业采取限制性措施，中国企业未来5年可能将被限制参与价值超过500万欧元的欧盟医疗器械公共招标 项目。 对此，外交部发言人林剑在例行记者会上回应称："中方始终坚持高水平对外开放，坚持维护市场经济原则和贸易规则，主张 ...